Effect Of DAAs For Treatment Of HCV On Normal Kidney

• Status: Unknown status
• Trial end date: 2018-10-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is to determine the effect of different direct acting antiviral drugs used for treatment of chronic HCV infected patients on normal kidney.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Antiviral Agents; Interferons; Ribavirin; Ritonavir; Sofosbuvir

Criteria

Inclusion Criteria:

• Both male and female patients with age above 18 years presented with chronic HCV infection (diagnosed by HCV RNA positive) with normal kidney functions, i.e.:

• Normal S.creatinine

• Normal urine analysis (without proteinuria, haematuria or abnormal casts).

• Normal renal sonography.

• and candidate for direct acting antiviral drugs.

Exclusion Criteria:

• Any chronic HCV patient with known renal disease.

• Patients with abnormal kidney functions, i.e.:

• Abnormal S.creatinine.

• Abnormal urine analysis (with proteinuria, haematuria or abnormal casts).

• Abnormal renal US

• Any other known renal disease (lupus nephritis, diabetic nephropathy).

• Severe co-morbidity as severe heart failure or malignancy.

• Other liver disease (autoimmune hepatitis, HBV, Wilson, ……).

• Decompansated liver disease (ascites, hepatic encephalopathy, …).